Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
CH1110760852
Tue, 13.08.2024
PolyPeptide Group
Media release – ad hoc announcement pursuant to Art. 53 LR
Solid progress in H1 2024 – Upgrade of 2024 full-year guidance – Mid-term target to double 2023 revenue by 2028
Baar, 13 August 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, today announced its results f [ … ]
Thu, 08.08.2024
PolyPeptide Group
PolyPeptide Group
/ Key word(s): Personnel
PolyPeptide appoints Chief Commercial Officer
08.08.2024 / 20:00 CET/CEST
Media release
PolyPeptide appoints Chief Commercial Officer
Baar, 8 August 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ing [ … ]
Wed, 10.04.2024
PolyPeptide Group
PolyPeptide Group
/ Key word(s): AGMEGM
PolyPeptide announces results of the annual General Meeting 2024
10.04.2024 / 19:23 CET/CEST
Media release
PolyPeptide announces results of the annual General Meeting 2024
Baar, 10 April 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleot [ … ]
Tue, 19.03.2024
PolyPeptide Group
PolyPeptide Group
/ Key word(s): AGMEGM
PolyPeptide publishes invitation to the annual General Meeting 2024
19.03.2024 / 07:00 CET/CEST
Media release
PolyPeptide publishes invitation to the annual General Meeting 2024
Baar, 19 March 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligon [ … ]
Tue, 12.03.2024
PolyPeptide Group
Media release – ad hoc announcement pursuant to Art. 53 LR
PolyPeptide with record revenue growth of 43% in H2 2023 versus H1 2023; operational improvements yielding increased profitability and cash flow
Baar, 12 March 2024 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical in [ … ]